Cargando…
Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP
New therapeutic strategies are needed for cutaneous T-cell lymphoma (CTCL), and the plant extract ingenol mebutate (PEP005) may be considered. PEP005 has been approved for actinic keratosis, and proapoptotic activities were described in different cancer cells. Here, we aimed to investigate its effic...
Autores principales: | Sumarni, Uly, Reidel, Ulrich, Eberle, Jürgen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146015/ https://www.ncbi.nlm.nih.gov/pubmed/33922439 http://dx.doi.org/10.3390/cells10050987 |
Ejemplares similares
-
Treatment of superficial basal cell carcinoma with ingenol mebutate gel, 0.05%
por: Bettencourt, Miriam S
Publicado: (2016) -
Ingenol mebutate treatment in keloids
por: De Felice, Bruna, et al.
Publicado: (2015) -
Tattoo removal with ingenol mebutate
por: Cozzi, Sarah-Jane, et al.
Publicado: (2017) -
Efficacy and safety of 0.05% ingenol mebutate in the treatment of basal cell carcinoma: A prospective study
por: Velin, Marine, et al.
Publicado: (2022) -
The Role of Ingenol Mebutate in the Treatment of Actinic Keratoses
por: Ali, Faisal R., et al.
Publicado: (2012)